^
Association details:
| Biomarker: | ROS1 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ROS1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
391P - Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: A referral tertiary cancer centre experience from a low-middle income country
Published date:
11/28/2022
Excerpt:
It is a retrospective analysis of ROS1-positive NSCLC patients registered between January 2015 to December 2021 for baseline characteristics, therapies received and clinical outcomes i.e. overall survival (OS) and progression free survival (PFS)….The overall response rate and disease control rate with ROS1 tyrosine kinase inhibitors were 76.32% and 89.47% respectively. The median OS and PFS for entire cohort were 37.9(95% CI 20.6-NA) months and 13(95% CI 9.92-26.1)months respectively while the same for patients on ROS1 TKI were 48.59(95% CI 37.85-NA) and 27.07(95% CI 13.0-50.8)months respectively.
